Russia begins trials of a new nasal vaccine against Covid-19 | News
Russia’s Gamaleya National Research Center for Epidemiology and Microbiology reported Thursday that they have begun clinical trials of a new nasal vaccine against Covid-19, which can also prevent infections with the Omicron variant.
PAHO warns that Covid-19 delays child development
The entity, which produces the drug, explained that the safety of the drug and its ability to produce antibodies against the virus will be analyzed during the first two phases of the study.
For her part, the specialist in clinical studies at Séchenov University, Irina Prónina, stated that “for now it is difficult to talk about the advantages compared to vaccination, but in the course of the clinical study we will explore its results.”
In turn, the pharmacologist Daria Kurguzova recalled that Sputnik V is “a vaccine that also began in the walls of the Séchenov University, it was we who began the first phase of testing in healthy volunteers in 2020, and here, in fact, now we are studying its nasal variant”.
The new drug is in the phase of clinical trials in people, with five initial volunteers who underwent a blood test, PCR, and who were then given this vaccine.
On Sputnik V, the representative of the World Health Organization (WHO) in Russia, Melita Vujnovic, declared that “ten vaccines have been included in the list of medicines recommended for emergency use, which means that they are used in emergencies. of public health, like now in a pandemic. Sixteen more candidates are pending, including Sputnik V.”
Until this day, Russia reported 26,586 new infections by Covid-19 for a total of 11,404,617, while the number of deaths was 657 deaths, totaling more than 321,000 deaths.